Cancer Cell Signaling: Targeting Signaling Pathways Toward Therapeutic Approaches to Cancer

Author:   Kasirajan Ayyanathan
Publisher:   Taylor & Francis Inc
ISBN:  

9781482299458


Pages:   410
Publication Date:   12 June 2014
Format:   Electronic book text
Availability:   Available To Order   Availability explained
We have confirmation that this item is in stock with the supplier. It will be ordered in for you and dispatched immediately.

Our Price $395.87 Quantity:  
Add to Cart

Share |

Cancer Cell Signaling: Targeting Signaling Pathways Toward Therapeutic Approaches to Cancer


Overview

Cell signaling is a field that studies how cells communicate to control basic activities and respond to their environment. When looking specifically at cancer cells, researchers can gain a better understanding of cancer on a cellular level, an understanding that may have implications for developing new treatments. The current volume provides an overview of the field and how various cell biology techniques are used to better understand cancer on a cellular level. This easily accessible reference volume offers a comprehensive look at the field of cancer cell signaling. Edited by a researcher from Florida Atlantic University, Cancer Cell Signaling: Targeting Signaling Pathways Towards Therapeutic Approaches to Cancer is an authoritative and easy-to-use reference.

Full Product Details

Author:   Kasirajan Ayyanathan
Publisher:   Taylor & Francis Inc
Imprint:   Spon Press
ISBN:  

9781482299458


ISBN 10:   1482299453
Pages:   410
Publication Date:   12 June 2014
Audience:   General/trade ,  College/higher education ,  General ,  Tertiary & Higher Education
Format:   Electronic book text
Publisher's Status:   Active
Availability:   Available To Order   Availability explained
We have confirmation that this item is in stock with the supplier. It will be ordered in for you and dispatched immediately.

Table of Contents

Introduction TGFss-Mediated Suppression of CD248 in Non-Cancer Cells Via Canonical SMAD-Dependent Signaling Pathways Is Uncoupled in Cancer Cells; Sahana Suresh Babu, Yanet Valdez, Andrea Xu, Alice M. O'Byrne, Fernando Calvo,Victor Lei, and Edward M. Conway Graded Inhibition of Oncogenic Ras-signaling by Multivalent Ras-Binding Domains; Martin Augsten, Anika Bottcher, Rainer Spanbroek, Ignacio Rubio, and Karlheinz Friedrich Direct Inhibition of PI3K in Combination with Dual HER2 Inhibitors Is Required for Optimal Antitumor Activity in HER2+ Breast Cancer Cells; Brent N. Rexer, Siprachanh Chanthaphaychith, Kimberly Brown Dahlman, and Carlos L. Arteaga Wnt3a Expression Is Associated with MMP-9 Expression in Primary Tumor and Metastatic Site in Recurrent or Stage IV Colorectal Cancer; Myung Ah Lee, Jin-Hee Park, Si Young Rhyu, Seong-Taek Oh, Won-Kyoung Kang, and Hee-Na Kim Wnt5a Promotes Migration of Human Osteosarcoma Cells by Triggering a Phosphatidylinositol-3 Kinase/Akt Signals; Ailiang Zhang, Shuanghua He, Xiaoliang Sun, Lianghua Ding, Xinnan Bao, and Neng Wang FOXA1 Promotes Tumor Cell Proliferation Through AR Involving the Notch Pathway in Endometrial Cancer; Meiting Qiu, Wei Bao, Jingyun Wang, Tingting Yang, Xiaoying He, Yun Liao, and Xiaoping Wan PKC alpha Regulates Netrin-1/UNC5B-Mediated Survival Pathway in Bladder Cancer; Jiao Liu, Chui-ze Kong, Da-xin Gong, Zhe Zhang, and Yu-yan Zhu Signaling Pathways in the Development of Infantile Hemangioma; Yi Ji, Siyuan Chen, Kai Li, Li Li, Chang Xu, and Bo Xiang STAG2 Is a Clinically Relevant Tumor Suppressor in Pancreatic Ductal Adenocarcinoma; Lisa Evers, Pedro A. Perez-Mancera, Elizabeth Lenkiewicz, Nanyun Tang, Daniela Aust, Thomas Knosel, Petra Ru ummele, Tara Holley, Michelle Kassner, Meraj Aziz, Ramesh K. Ramanathan, Daniel D. Von Hoff, Holly Yin, Christian Pilarsky, and Michael T. Barrett Molecular Determinants of Context-Dependent Progesterone Receptor Action in Breast Cancer; Christy R. Hagan and Carol A. Lange Architecture of Epigenetic Reprogramming Following Twist1-Mediated Epithelial-Mesenchymal Transition; Gabriel G. Malouf, Joseph H. Taube, Yue Lu, Tapasree Roysarkar, Shoghag Panjarian, Marcos R.H. Estecio, Jaroslav Jelinek, Jumpei Yamazaki, Noel J-M Raynal, Hai Long, Tomomitsu Tahara, Agata Tinnirello, Priyanka Ramachandran, Xiu-Ying Zhang, Shoudan Liang, Sendurai A. Mani, and Jean-Pierre J. Issa Stability and Prognostic Value of Slug, Sox9 and Sox10 Expression in Breast Cancers Treated with Neoadjuvant Chemotherapy; Cosima Riemenschnitter, Ivett Teleki, Verena Tischler, Wenjun Guo, and Zsuzsanna Varga Combination Therapy of Anti-Cancer Bioactive Peptide with Cisplatin Decreases Chemotherapy Dosing and Toxicity to Improve the Quality of Life in Xenograft Nude Mice Bearing Human Gastric Cancer; Xiulan Su, Chao Dong, Jialing Zhang, Liya Su, Xuemei Wang, Hongwei Cui, and Zhong Chen Combination of Sulindac and Dichloroacetate Kills Cancer Cells via Oxidative Damage; Kasirajan Ayyanathan, Shailaja Kesaraju, Ken Dawson-Scully, and Herbert Weissbach Index

Reviews

Author Information

Kasirajan Ayyanathan, PhD, received his PhD from the Department of Biochemistry, Indian Institute of Science, one of the premier research institutions in India. Subsequently, at Temple University School of Medicine, Philadelphia, Pennsylvania, USA, he conducted post-doctoral research on the signal transduction by purinergic receptors, a class of G-Protein Coupled Receptors (GPCR), in erythroleukemia cancer cells. Next, he was trained as a staff scientist at the Wistar Institute, Philadelphia, for almost ten years and studied transcription regulation, chromatin, and epigenetic regulatory mechanisms in cancer before becoming an associate professor at Florida Atlantic University (FAU). Currently, he is at the Center for Molecular Biology and Biotechnology as a research associate professor at FAU. He is the recipient of Chern Memorial Award, presented by the Wistar Institute, and Howard Temin Career Research Award, presented by the National Cancer Institute, USA.Dr. Ayyanathan is well trained in molecular biology, cell biology, and biochemistry with main focus on studying transcription factors and gene regulation. He has contributed to several projects such as on the generation of conditional transcriptional repressors that are directed against the endogenous oncogenes to inhibit malignant growth, on the establishment of stable cell lines that express chromatin integrated transcriptional repressors and reporter genes in order to study the epigenetic mechanisms of KRAB repression, and on identification of novel SNAG repression domain interacting proteins in order to understand their roles in transcriptional repression and oncogenesis. Dr. Ayyanathan has published several research articles in peer-reviewed articles in these subject areas.

Tab Content 6

Author Website:  

Countries Available

All regions
Latest Reading Guide

RGJ26

 

Shopping Cart
Your cart is empty
Shopping cart
Mailing List